Article Data

  • Views 266
  • Dowloads 114

Original Research

Open Access

Mammographic features in infertile women as a potential risk for breast cancer: a preliminary study

  • M.L. Meggiorini1,*,
  • V. Cipolla2
  • F. Rech1
  • L. Labi1
  • A. Vestri3
  • C. de Felice2

1Department of Gynecology and Obstetrics, “Sapienza” University of Rome, Rome, Italy

2Department of Radiological Sciences, “Sapienza” University of Rome, Rome, Italy

3Department of Public Health, “Sapienza” University of Rome, Rome, Italy

DOI: 10.12892/ejgo20120151 Vol.33,Issue 1,January 2012 pp.51-55

Published: 10 January 2012

*Corresponding Author(s): M.L. Meggiorini E-mail: marialetizia.meggiorini@uniroma1.it

Abstract

The purpose of the present study was to evaluate breast mammographic features, particularly mammographic density in a selected population of infertile women and to assess if these women should be considered at higher risk for breast cancer. The prevalence of female infertility in Western countries is approximately 10-15% and since causes affecting the female are involved in 35-40%, concerns have developed about the future health of these women, specifically whether infertility could represent a risk factor for future cancer development. Moreover, infertility is now often treated with medication and procedures that could modify the hormonal environment and be cofactors in the cellular changes towards cancer development. Mammographic breast density is a useful marker for breast cancer risk and breast density is considered one of the strongest risk factors for breast cancer. Breast density is associated with known breast cancer risk factors such as reproductive and menstrual factors including serum estrogen and progesterone concentrations. in Italy the National Federation for Breast Cancer (FONCAM) guidelines suggest the usefulness of mammography from 35 years of age for women who undergo infertility hormone therapy (FONCAM Guidelines, 2005). According to this recommendation 294 women aged >= 35, with primary infertility, sent to our breast service before joining an IVF program were recruited and then underwent clinical examination and X-ray mammography. Women were divided into two groups: dense breast (DB) and non-dense breast (NDB). Univariate analysis was employed to evaluate if there was an association between mammographic density and other risk factors. Evaluation of mammagraphic features showed the presence of BI-RADs C and D in the sample of 200 (68%) patients with DB and in 94 (32%) patients with NDB BI-RADS A and B. Univariate analysis showed that there were no statistically significant differences between the groups BD and NDB as regards age at mammography, age at menarche, BMI and family history for breast cancer, while ovulatory etiology of infertility was found to be associated with high mammographic density (p < 0.05). In conclusion, bearing in mind that 68% of our study sample had high breast density, we can assume that patients with primary infertility might represent a group at high risk for breast cancer, particularly if infertility is due to an ovulatory factor. We suggest breast screening from the age of 35 in infertile patients who undergo treatment with fertility drugs in accordance with FONCAM recommendations. This might allow the identification of higher risk patients who need more closely monitored breast examinations.

Keywords

Infertility; Fertility drugs; Breast density; Breast cancer risk

Cite and Share

M.L. Meggiorini,V. Cipolla,F. Rech,L. Labi,A. Vestri,C. de Felice. Mammographic features in infertile women as a potential risk for breast cancer: a preliminary study. European Journal of Gynaecological Oncology. 2012. 33(1);51-55.

References

[1] Crosignani P.G., Rubin B.: “The ESHRE Capri Workshop. Guidelines to the prevalence, diagnosis, treatment and management of infertility”. Hum. Reprod., 1996, 11, 1775.

[2] Stephen E., Chandra A.: “Updated projections of infertility in the United States: 1995-2025”. Fertil. Steril., 1998, 70, 30.

[3] Wysowsky D.K.: “Use of fertility drugs in the United States, 1973 through 1991”. Fertil. Steril., 1993, 60, 1096.

[4] Nyboe Andersen A., V. Goossens V., Bhattacharya S., Ferraretti A.P., Kupka M.S., de Mouzon J., K.G. Nygren; European IVF monitoring (EIM) Consortium, for the European Society of Human Reproduction and Embryology (ESHRE): “Assisted reproductive technology and intrauterine inseminations in Europe, 2005: results generated from European registers by ESHRE”. Hum. Reprod., 2009, 24, 1267.

[5] Sovino H., Sir-Petermann T., Devoto L.: “Clomiphene citrate and ovulation induction”. Reprod. Biomed. Online, 2002, 4, 303.

[6] Derman S.G., Adashi E.Y.: “Adverse effects of fertility drugs”. Drug Saf., 1994, 11, 408.

[7] MacLachlan V., Besanko M., O’Shea F., Wade H., Wood C., Trounson A., Healy D.L.: “A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization”. N. Engl. J. Med., 1989, 320, 1233.

[8] Zreik T.G., Mazloom A., Chen Y., Vannucci M., Pinnix C.C., Fulton S. et al.: “Fertility drugs and the risk of breast cancer: a meta-analysis and review”. Breast Cancer Res. Treat., 2010, 124, 13.

[9] Burkman R.T., Tang M.T., Malone K.E., Marchbanks P.A., McDonald J.A., Folger S.G. et al.: “Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women’s Contraceptive and Reproductive Experiences Study”. Fertil. Steril., 2003, 79, 844.

[10] Lerner-Geva L., Keinan-Boker L., Blumstein T., Boyko V., Olmar L., Mashiach S. et al.: “Infertility, ovulation induction treatments and the incidence of breast cancer -a historical prospective cohort of Israeli women”. Breast Cancer Res. Treat., 2006, 100, 201.

[11] Potashnik G., Lerner-Geva L., Genkin L., Chetrit A., Lunenfeld E., Porath A.: “Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study”. Fertil. Steril., 1999, 71, 853.

[12] Brinton L.A., Scoccia B., Moghissi K.S., Westhoff C.L., Althuis M.D., Mabie J.E. et al.: “Breast cancer risk associated with ovulation-stimulating drugs”. Hum. Reprod., 2004, 19, 2005.

[13] Orgeas C.C., Sanner K., Hall P., Conner P., Holte J., Nilsson S.J. et al.: “Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study”. Am. J. Obstet. Gynecol., 2009, 200, 72.e1.

[14] Rossing M.A., Daling J.R., Weiss N.S., Moore D.E., Self S.G.: “Risk of breast cancer in a cohort of infertile women”. Gynecol. Oncol., 1996, 60, 3.

[15] Terry K.L., Willett W.C., Rich-Edwards J.W., Michels K.B.: “A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer”. Arch. Intern. Med., 2006, 166, 2484.

[16] Dor J., Lerner-Geva L., Rabinovici J., Chetrit A., Levran D., Lunenfeld B. et al.: “Cancer incidence in a cohort of infertile women who underwent in vitro fertilization”. Fertil. Steril., 2002, 77, 324.

[17] Modan B., Ron E., Lerner-Geva L., Blumstein T., Menczer J., Rabinovici J. et al.: “Cancer incidence in a cohort of infertile women”. Am. J. Epidemiol., 1998, 147, 1038.

[18] Doyle P., Maconochie N., Beral V., Swerdlow A.J., Tan S.L.: “Cancer incidence following treatment for infertility at a clinic in the UK”. Hum. Reprod., 2002, 17, 2209.

[19] Ricci E., Parazzini F., Negri E., Marsico S., La Vecchia C.: “Fertility drugs and the risk of breast cancer”. Hum. Reprod., 1999, 14, 1653.

[20] Venn A., Watson L., Bruinsma F., Giles G., Healy D.: “Risk of cancer after use of fertility drugs with in vitro fertilisation”. Lancet, 1999, 354, 1586.

[21] Braga C., Negri E., La Vecchia C., Parazzini F., Dal Maso L., Franceschi S.: “Fertility treatment and risk of breast cancer”. Hum. Reprod., 1996, 11, 300.

[22] Gauthier E., Paoletti X., Clavel-Chapelon F. : “Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study”. Hum. Reprod., 2004, 19, 2216.

[23] Boyd N.F., Lockwood G.A., Byng J., Tritchler D.L., Yaffe M.: “Mammographic densities and breast cancer risk”. Cancer Epidemiol. Biomarkers Prev., 1998, 7, 1133.

[24] Martin L.J., Boyd N.: “Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence”. Breast Cancer Res., 2008, 10, 1.

[25] Perry N., Broeders M., de Wolf C., Törnberg S., Holland R., von Karsa L.: “European guidelines for quality assurance in mammography screening”. 4th Ed, 2006.

[26] Eberl M.M., Fox C.H., Edge S.B., Carter C.A., Mahoney M.C.: “BI RADS classification for management of abnormal mammograms”. J. Am. Board Fam. Med., 2006, 19, 161.

[27] Lee C.H., Dershaw D.D., Kopans D., Evans P., Monsees B., Monticciolo D. et al.: “Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer”. J. Am. Coll. Radiol., 2010, 7, 18.

[28] Hirsch B.R., Lyman G.H.: “Breast cancer screening with mammography”. Curr. Oncol. Rep., 2011, 13, 63.

[29] McCormack V.A., dos Santos Silva I.: “Breast density and parenchymal patterns as markers of breast cancer risk: a metaanalysis”. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 1159.

[30] Byrne C., Schairer C., Wolfe J., Parekh N., Salane M., Brinton L.A. et al.: “Mammographic features and breast cancer risk: effects with time, age, and menopause status”. J. Natl. Cancer Inst., 1995, 87, 1622.

[31] Pankow J.S., Vachon C.M., Kuni C.C., King R.A., Arnett D.K., Grabrick D.M. et al.: “Genetic analysis of mammographic breast density in adult women: evidence of a gene effect”. J. Natl. Cancer Inst., 1997, 89, 549.

[32] Boyd N.F., Guo H., Martin L.J., Sun L., Stone J., Fishell E. et al.: “Mammographic density and the risk and detection of breast cancer”. N. Engl. J. Med., 2007, 356, 227.

[33] Egan R.L., Mosteller R.C.: “Breast cancer mammography patterns”. Cancer, 1977, 40, 2087.

[34] Vachon C.M., van Gils C.H, Sellers T.A., Ghosh K., Pruthi S.: ...

[35] Brandt K.R., Pankratz V.S. et al.: “Mammographic density, breast cancer risk and risk prediction”. Breast Cancer Research, 2007, 9, 217.

[36] De Waard F., Rombach J.J., Collette HJA., Slotboom B.: “Breast cancer risk associated with reproductive factors and breast parenchymal patterns”. J. Natl Cancer Inst., 1984, 72, 1277.

[37] Russo J., Rivera R., Russo I.H.: “Influence of age and parity on the development of the human breast”. Breast Cancer Res. Treat., 1992, 23, 211.

[38] van Gils C.H., Hendriks J.H.C.L., Otten J.D.M., Holland R., Verbeek A.L.M.: “Parity and mammographic breast density in relation to breast cancer risk: indication of interaction”. Eur. J. Cancer Prev., 2000, 9, 105.

[39] Speroff L., Glass R.H., Kase N.G.: “Investigation of the infertile couple”. In: Clinical Gynecological Endocrinology and Infertility. 5th ed. Baltimore, MD: Williams & Wilkins, 1994.

[40] Boyd N.F., Byng J.W., Jong R.A., Fishell E.K., Little L.E., Miller A.B. et al.: “Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study”. J. Natl. Cancer Inst., 1995, 87, 670.

[41] Ziv E., Shepherd J., Smith-Bindman R., Kerlikowske K.: “Mammographic breast density and family history of breast cancer”. J. Natl. Cancer Inst., 2005, 95, 556.

[42] Brisson J., Morrison A.S., Kopans D.B.: “Height and weight, mammographic features of breast tissue, and breast cancer risk”. Am. J. Epidemiol., 1984, 119, 371.

[43] Grove J.S., Goodman M.J., Gilbert F., Mi M.P.: “Factors associated with mammographic pattern”. Br. J. Radiol., 1985, 58, 21.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top